Antoni Wiedlocha funded by the EEA Poland-Norway grants
The proposal "Novel targeted therapy based on dual warhead conjugates against FGFR dependent cancers", with senior scientist Antoni Wiedlocha at Department of Molecular Cell Biology, Institute for Cancer Research, as Norwegian partner and professor Jacek Otlewski at the University of Wroclaw as Polish parther, has been awarded funding from the EEA Poland-Norway grants under the "Applied Research" programme.
From the National Centre for Research and Development in Poland:
Published in major journals, first or last author from Oslo University Hospital.
Stamnaes J, Stray D, Stensland M, Sarna VK, Nyman TA, Lundin KEA, Sollid LM(2021) In Well-Treated Celiac Patients Low-Level Mucosal Inflammation Predicts Response to 14-day Gluten Challenge Adv Sci (Weinh), 8(4), 2003526 DOI 10.1002/advs.202003526, PubMed 33643806
Jiang X, Bergquist A, Löscher BS, Venkatesh G, Mold JE, Holm K, Laerdahl JK, Skånland SS, Maleki KT, Cornillet M, Taskén K, Franke A, Karlsen TH, Björkström NK, Melum E(2021) A heterozygous germline CD100 mutation in a family with primary sclerosing cholangitis Sci Transl Med, 13(582) DOI 10.1126/scitranslmed.abb0036, PubMed 33627483
Ianevski A, Lahtela J, Javarappa KK, Sergeev P, Ghimire BR, Gautam P, Vähä-Koskela M, Turunen L, Linnavirta N, Kuusanmäki H, Kontro M, Porkka K, Heckman CA, Mattila P, Wennerberg K, Giri AK, Aittokallio T(2021) Patient-tailored design for selective co-inhibition of leukemic cell subpopulations Sci Adv, 7(8) DOI 10.1126/sciadv.abe4038, PubMed 33608276